PROFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Profound Medical Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.86−0.15 (-2.50%)
Close on Oct 19, 2026
- Market cap
- $213.01M
- P/E (TTM)
- 4.2
- Dividend yield
- –
Profound Medical Corp. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Recurring - non-capital | $10.45M | $10.40M | $9.73M | $10.12M | $8.70M | $8.60M | $8.24M | 54.8% | +20.1% |
| Capital equipment | $8.63M | $8.41M | $6.37M | $4.18M | $3.14M | $3.26M | $2.44M | 45.2% | +175.2% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | $12.09M | $12.32M | $12.25M | $11.40M | $8.61M | $7.74M | $7.35M | 63.3% | +40.4% |
| Canada | $6.26M | $5.80M | $3.08M | $2.21M | $2.41M | $3.19M | $2.44M | 32.8% | +159.9% |
| Germany | $739.00K | $697.00K | $773.00K | $686.00K | $820.00K | $940.00K | $891.00K | 3.9% | -9.9% |
From the segment and revenue-disaggregation notes of Profound Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.